Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Overall survival · Adult patients with follicular lymphoma
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · Adult patients with follicular lymphoma
The intervention showed no clear difference in treatment‐related mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Adult patients with follicular lymphoma
The intervention probably leads to lower progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies AML/MDS · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies AML/MDS (low certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies Solid cancer · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies Solid cancer (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Adult patients with follicular lymphoma
1 finding from 1 review